HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Association of ECRG2 TCA short tandem repeat polymorphism with the risk of oesophageal cancer in a North Indian population.

Abstract
Oesophageal cancer-related gene (ECRG2) is a tumour suppressor gene and it has been suggested that a triplet TCA short tandem repeat (STR) in the noncoding region of exon 4 plays a role in genetic susceptibility to oesophageal cancer. In the present study, ECRG2 STR polymorphism was studied in 134 patients with oesophageal cancer and 194 controls, using PCR and polyacrylamide gel electrophoresis. The results showed a higher frequency of the ECRG2 TCA (3)/TCA (4) genotype in cancer patients than in controls (odds ratio 2.6, 95% CI 1.0-6.4, p = 0.03). The association of the ECRG2 TCA (3)/TCA (4) genotype with clinical characteristics showed an increased risk for squamous cell histology (2.8, 95% CI 1.1-7.1, p = 0.03), while no association with tumor location or lymph node involvement was observed. Interaction of tobacco, alcohol and occupational exposure with the ECRG2 genotypes did not show modulation of risk. In conclusion, the ECRG2 TCA (3)/TCA (4) genotype is associated with the risk of oesophageal carcinoma in a North Indian population.
AuthorsMeenu Jain, Shaleen Kumar, Uday C Ghoshal, Balraj Mittal
JournalClinical and experimental medicine (Clin Exp Med) Vol. 8 Issue 2 Pg. 73-8 (Jun 2008) ISSN: 1591-8890 [Print] Italy
PMID18618216 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Proteinase Inhibitory Proteins, Secretory
  • SPINK7 protein, human
  • Serine Peptidase Inhibitors, Kazal Type
  • Tumor Suppressor Proteins
Topics
  • Esophageal Neoplasms (etiology)
  • Female
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Male
  • Microsatellite Repeats
  • Middle Aged
  • Proteinase Inhibitory Proteins, Secretory
  • Risk
  • Serine Peptidase Inhibitors, Kazal Type
  • Tumor Suppressor Proteins (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: